EMBC vs. SIBN, IRMD, SILK, OFIX, TMCI, KIDS, ATRI, NVRO, SKIN, and PLSE
Should you be buying Embecta stock or one of its competitors? The main competitors of Embecta include SI-BONE (SIBN), Iradimed (IRMD), Silk Road Medical (SILK), Orthofix Medical (OFIX), Treace Medical Concepts (TMCI), OrthoPediatrics (KIDS), Atrion (ATRI), Nevro (NVRO), Beauty Health (SKIN), and Pulse Biosciences (PLSE). These companies are all part of the "surgical & medical instruments" industry.
Embecta (NASDAQ:EMBC) and SI-BONE (NASDAQ:SIBN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, community ranking, valuation and profitability.
Embecta has a net margin of 4.93% compared to SI-BONE's net margin of -31.20%. Embecta's return on equity of -18.66% beat SI-BONE's return on equity.
SI-BONE received 157 more outperform votes than Embecta when rated by MarketBeat users. Likewise, 66.81% of users gave SI-BONE an outperform vote while only 0.00% of users gave Embecta an outperform vote.
93.8% of Embecta shares are owned by institutional investors. Comparatively, 98.1% of SI-BONE shares are owned by institutional investors. 0.3% of Embecta shares are owned by insiders. Comparatively, 5.4% of SI-BONE shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Embecta currently has a consensus price target of $16.00, indicating a potential upside of 54.59%. SI-BONE has a consensus price target of $26.67, indicating a potential upside of 74.29%. Given SI-BONE's stronger consensus rating and higher possible upside, analysts plainly believe SI-BONE is more favorable than Embecta.
In the previous week, Embecta and Embecta both had 4 articles in the media. Embecta's average media sentiment score of 0.09 beat SI-BONE's score of 0.00 indicating that Embecta is being referred to more favorably in the media.
Embecta has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Comparatively, SI-BONE has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500.
Embecta has higher revenue and earnings than SI-BONE. SI-BONE is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.
Summary
SI-BONE beats Embecta on 9 of the 17 factors compared between the two stocks.
Get Embecta News Delivered to You Automatically
Sign up to receive the latest news and ratings for EMBC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EMBC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
